A carregar...
Long-term Survival and Cost-effectiveness Associated With Axicabtagene Ciloleucel vs Chemotherapy for Treatment of B-Cell Lymphoma
IMPORTANCE: Axicabtagene ciloleucel, a chimeric antigen receptor T-cell therapy, represents a new and potentially curative treatment option for B-cell lymphoma. It is expected to have long-term survival benefits; however, long-term survival data are limited. OBJECTIVE: To estimate the long-term surv...
Na minha lista:
Publicado no: | JAMA Netw Open |
---|---|
Main Authors: | , , , , , , , |
Formato: | Artigo |
Idioma: | Inglês |
Publicado em: |
American Medical Association
2019
|
Assuntos: | |
Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6484589/ https://ncbi.nlm.nih.gov/pubmed/30794298 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamanetworkopen.2019.0035 |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|